Trials / Completed
CompletedNCT00976716
An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain
An Open-Label, Multicenter Study To Evaluate The Efficacy, Safety And Tolerability Of Celecoxib (YM177) In Patients With Posttraumatic Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate efficacy, safety and tolerability of Celecoxib in patients with posttraumatic pain for the duration of 8 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | Day 1 * The first dose: Celecoxib 400mg * The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8) \- Celecoxib 200mg twice daily |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2009-09-14
- Last updated
- 2021-02-02
- Results posted
- 2011-05-19
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00976716. Inclusion in this directory is not an endorsement.